PL1937065T3 - Nowe sole lizynowe pochodnych kwasu 4-((fenoksyalkilo)tio)fenoksyoctowewgo - Google Patents

Nowe sole lizynowe pochodnych kwasu 4-((fenoksyalkilo)tio)fenoksyoctowewgo

Info

Publication number
PL1937065T3
PL1937065T3 PL06803483T PL06803483T PL1937065T3 PL 1937065 T3 PL1937065 T3 PL 1937065T3 PL 06803483 T PL06803483 T PL 06803483T PL 06803483 T PL06803483 T PL 06803483T PL 1937065 T3 PL1937065 T3 PL 1937065T3
Authority
PL
Poland
Prior art keywords
phenoxyalkyl
thio
acid derivatives
phenoxyacetic acid
lysine salts
Prior art date
Application number
PL06803483T
Other languages
English (en)
Inventor
Ahmed F Abdel-Magid
Steven J Mehrman
Armin Roessler
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL1937065T3 publication Critical patent/PL1937065T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL06803483T 2005-09-14 2006-09-13 Nowe sole lizynowe pochodnych kwasu 4-((fenoksyalkilo)tio)fenoksyoctowewgo PL1937065T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71713705P 2005-09-14 2005-09-14
PCT/US2006/035617 WO2007033231A2 (en) 2005-09-14 2006-09-13 Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives
EP06803483.4A EP1937065B1 (en) 2005-09-14 2006-09-13 Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives

Publications (1)

Publication Number Publication Date
PL1937065T3 true PL1937065T3 (pl) 2015-07-31

Family

ID=37865545

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06803483T PL1937065T3 (pl) 2005-09-14 2006-09-13 Nowe sole lizynowe pochodnych kwasu 4-((fenoksyalkilo)tio)fenoksyoctowewgo

Country Status (28)

Country Link
US (2) US7709682B2 (pl)
EP (1) EP1937065B1 (pl)
JP (1) JP5467770B2 (pl)
KR (5) KR20130100800A (pl)
CN (1) CN101304656B (pl)
AR (1) AR058044A1 (pl)
AU (1) AU2006291006B2 (pl)
BE (1) BE2025C533I2 (pl)
BR (1) BRPI0615835B8 (pl)
CA (1) CA2622722C (pl)
DK (1) DK1937065T3 (pl)
ES (1) ES2535427T3 (pl)
FI (1) FIC20253005I1 (pl)
FR (1) FR25C1030I2 (pl)
GT (1) GT200600420A (pl)
HN (1) HN2006032171A (pl)
HU (2) HUE025185T2 (pl)
JO (1) JO3006B1 (pl)
LT (1) LTC1937065I2 (pl)
NL (1) NL301339I2 (pl)
NZ (1) NZ566504A (pl)
PE (1) PE20070434A1 (pl)
PL (1) PL1937065T3 (pl)
PT (1) PT1937065E (pl)
SI (1) SI1937065T1 (pl)
TW (1) TWI414510B (pl)
UY (1) UY29791A1 (pl)
WO (1) WO2007033231A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414534B8 (pt) * 2003-09-19 2021-05-25 Janssen Pharmaceutica Nv ácidos 4-((fenoxialquila)tio)-fenoxiacéticos e análogos e composição farmacêutica compreendendo-os
SI1667964T1 (sl) * 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
KR20110091680A (ko) 2008-10-17 2011-08-12 메타볼렉스, 인코포레이티드 작고 조밀한 ｌｄｌ 입자를 감소시키는 방법
EP2459176B1 (en) 2009-07-31 2017-09-27 Grünenthal GmbH Crystallization method and bioavailability
US20160016982A1 (en) * 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2638072T3 (es) * 2010-02-06 2017-10-18 Grünenthal GmbH Método de cristalización y biodisponibilidad
WO2012030165A2 (ko) 2010-08-31 2012-03-08 서울대학교산학협력단 P P A R δ 활성물질의 태자재프로그래밍용도
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US20160279085A1 (en) * 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
EA201691039A1 (ru) 2013-11-20 2016-11-30 Саймабэй Терапьютикс, Инк. Лечение гомозиготной семейной гиперхолестеринемии
DK3119384T3 (en) * 2014-03-20 2018-12-03 Cymabay Therapeutics Inc TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
UA121208C2 (uk) 2014-04-11 2020-04-27 Сімабей Терапьютікс, Інк. Лікування нажхп та насг
CN106470675A (zh) * 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
JP6906510B2 (ja) 2016-05-16 2021-07-21 帝人ファーマ株式会社 キノリン誘導体の結晶
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20200276178A1 (en) 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
LT3973959T (lt) 2017-09-26 2025-01-10 Cymabay Therapeutics, Inc. Cholestazinio niežulio gydymas seladelparu
KR20210092754A (ko) 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료
EP3880187A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
US20230008367A1 (en) 2019-09-26 2023-01-12 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
WO2021098885A1 (zh) * 2019-11-21 2021-05-27 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
SMT202400302T1 (it) 2021-02-01 2024-09-16 Cymabay Therapeutics Inc Trattamento di colangiopatie con seladelpar
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
US20240252499A1 (en) 2023-01-29 2024-08-01 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
WO2024159051A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
WO2024175026A1 (zh) * 2023-02-24 2024-08-29 哈尔滨三联药业股份有限公司 含氮杂环类化合物及其医药用途
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
US20260060948A1 (en) 2024-07-31 2026-03-05 Cymabay Therapeutics, Inc. Methods for treating liver disease
WO2026030479A1 (en) * 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Process for making seladelpar

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4125732A (en) * 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3169761D1 (en) 1981-01-09 1985-05-09 Fisons Plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
EP0106565B1 (en) 1982-09-30 1986-09-10 Merck Frosst Canada Inc. Leukotriene antagonists, their production, and compositions containing them
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) * 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) * 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
CA2092152A1 (en) * 1992-03-23 1993-09-24 Azuma Igarashi Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
CA2244831A1 (en) 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
ES2320181T3 (es) 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
HUP0400280A3 (en) * 2001-06-07 2006-01-30 Ligand Pharmaceuticals Inc San Modulators of peroxisome proliferator activated receptors, process for their preparation and pharmaceutical compositions containing them
BR0211414A (pt) 2001-07-30 2004-08-17 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas
IL160304A0 (en) 2001-08-10 2004-07-25 Nippon Chemiphar Co ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR delta
PT1445258E (pt) 2001-10-12 2009-07-02 Nippon Chemiphar Co Activador para o receptor delta activado por proliferador de peroxissoma
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
JP4383177B2 (ja) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション ｈＰＰＡＲ活性化剤
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
BR0314335A (pt) * 2002-09-05 2005-07-26 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
PL376704A1 (pl) * 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki przydatne w leczeniu chorób, w których pośredniczy PPAR
BR0315683A (pt) * 2002-10-28 2005-08-30 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento e/ou prevenção de condições mediadas por receptores nucleares e para o tratamento e/ou prevenção do diabete do tipo i, diabete do tipo ii, tolerância à glicose prejudicada, resistência à insulina ou obesidade
CA2515481A1 (en) 2003-02-14 2004-09-02 Biogen Idec Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
US20060257987A1 (en) * 2003-08-20 2006-11-16 Gonzalez Valcarcel Isabel Cris Ppar modulators
SI1667964T1 (sl) * 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
BRPI0414534B8 (pt) * 2003-09-19 2021-05-25 Janssen Pharmaceutica Nv ácidos 4-((fenoxialquila)tio)-fenoxiacéticos e análogos e composição farmacêutica compreendendo-os
KR20060109925A (ko) 2003-10-31 2006-10-23 얀센 파마슈티카 엔.브이. 퍼옥시좀 증식체-활성화된 수용체(ｐｐａｒ) 이중작용제로서 유용한 페녹시아세트산 유도체
EP1745047B1 (en) 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
BRPI0512951A (pt) * 2004-07-01 2008-04-15 Hoffmann La Roche compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha)
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) * 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
BRPI0615835A2 (pt) 2011-05-31
FIC20253005I1 (fi) 2025-07-31
US7709682B2 (en) 2010-05-04
ES2535427T3 (es) 2015-05-11
HUS2500034I1 (hu) 2025-09-28
SI1937065T1 (sl) 2015-05-29
AU2006291006A1 (en) 2007-03-22
KR20180079468A (ko) 2018-07-10
HN2006032171A (es) 2011-03-15
CA2622722A1 (en) 2007-03-22
BRPI0615835B1 (pt) 2020-04-22
NZ566504A (en) 2010-11-26
HK1122699A1 (en) 2009-05-29
WO2007033231A3 (en) 2007-10-11
KR20150013952A (ko) 2015-02-05
US20070060649A1 (en) 2007-03-15
CN101304656A (zh) 2008-11-12
DK1937065T3 (en) 2015-02-09
JO3006B1 (ar) 2016-09-05
US8669288B2 (en) 2014-03-11
LTPA2025530I1 (pl) 2025-08-25
TWI414510B (zh) 2013-11-11
CN101304656B (zh) 2013-03-13
PE20070434A1 (es) 2007-05-14
KR20130100800A (ko) 2013-09-11
EP1937065A2 (en) 2008-07-02
LTC1937065I2 (pl) 2025-12-29
WO2007033231A2 (en) 2007-03-22
BE2025C533I2 (pl) 2026-02-02
AR058044A1 (es) 2008-01-23
JP5467770B2 (ja) 2014-04-09
KR20080046695A (ko) 2008-05-27
EP1937065B1 (en) 2015-01-28
AU2006291006B2 (en) 2012-09-13
FR25C1030I2 (fr) 2026-02-06
FR25C1030I1 (fr) 2025-09-26
BRPI0615835B8 (pt) 2021-05-25
CA2622722C (en) 2016-04-19
TW200804256A (en) 2008-01-16
JP2009514797A (ja) 2009-04-09
US20110105616A1 (en) 2011-05-05
GT200600420A (es) 2007-05-08
EP1937065A4 (en) 2010-07-21
UY29791A1 (es) 2006-12-29
PT1937065E (pt) 2015-03-04
KR20160079129A (ko) 2016-07-05
NL301339I2 (nl) 2025-09-16
HUE025185T2 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
PL1937065T3 (pl) Nowe sole lizynowe pochodnych kwasu 4-((fenoksyalkilo)tio)fenoksyoctowewgo
IL186435A (en) Pharmaceutical formulation for oral administration of choline salt of acid 2 - [4 - (4 - chlorobenzoyl) phenoxy] - 2 - methyl propanoic
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
DK2173730T3 (da) Hidtil ukendte forbindelser 951: biphenyloxypropansyre som crth2-modulator og mellemprodukter
DK1942760T3 (da) Fodtøj med mulighed for uafhængig artikulation af tådele
UY29575A1 (es) Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico
DK2470518T3 (da) Esterderivater af 2,5-furandicarboxylsyre og deres anvendelse som blødgørere
ATE427296T1 (de) Phenoxyessigsaurederivate
BRPI0910178A2 (pt) "composto de fórmula (i), composto de fórmula (vi), composição de fungicidas e método para o controle de fungo fitopatogênico de culturas"
BRPI0810660A2 (pt) Derivados do ácido lipóico
HUE043158T2 (hu) (Tio)karboxamid-származékot és fungicid vegyületet tartalmazó hatóanyag készítmények
ATE394094T1 (de) Tablette enthaltend 3-((2-ä(4- (hexyloxycarbonylamino-imino-methyl)-phenylamin )-methylü-1-methyl-1h-benzimidazol-5-carbonyl)- pyridin-2-yl-amino)-propionsäure-ethylester oder dessen salze
SI2076501T1 (sl) Kristalinične oblike 3-(5-(2-florofenil)-1,2,4) oksadiazol-3-il)-benzojske kisline
DK2057115T3 (da) 4-substituerede phenoxyphenyleddikesyrederivater
PL1667964T3 (pl) Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
WO2006114415A3 (de) Physiologisch verträgliche salze von 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
CL2008000796A1 (es) Uso de 4-(2-(4-metilfenilsulfanil)fenil)piperidina y sales de adicion de acidos de la misma para el tratamiento del adhd, melancolia, depresion o sintomas residuales de la depresion; y dicho compuesto.
DK1860098T3 (da) Nyt anthranilsyrderivat eller salt deraf
EP2196460A4 (en) Sulphonic acid salt compound of a 4-carbamoyl-5-hydroxyimidazole derivative
DK2022497T3 (da) Oral sammensætning, omfattende 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxyphenylpropionsyre eller salt deraf
PL2722046T3 (pl) Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
PL2040691T3 (pl) Wodna formulacja farmaceutyczna kwasu 4-[((4-karboksybutylo)-{2-[(4-fenetylobenzylo)oksy]fenetylo}amino)metylo]benzoesowego
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
PL2187863T3 (pl) Przeciwpotowe sole okso-heksameryczny cyrkon-oktaaminokwasu